GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...
European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.
A new computational tool could help researchers identify promising drug combinations for treating cancer, according to a new ...
Scientists have developed retriever, a computational tool that extracts disease-specific drug response signatures to predict the best combinations for cancer treatment.
Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use of nanoscale materials ...
GSK and the University of Oxford have joined hands to focus on the potential of cancer prevention through vaccination. The ...
The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.
GSK flagged the US$1.15 billion acquisition of US-based precision medicine company IDRX, which is currently in Phase I trials ...
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...
The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.